IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

January 15, 2027

Study Completion Date

January 15, 2028

Conditions
Metastatic Uveal Melanoma
Interventions
DRUG

IDE196

Dosed orally, twice daily

DRUG

Crizotinib

Dosed orally, twice daily

DRUG

Pembrolizumab

IV administration every 3 weeks

DRUG

Ipilimumab

IV administration every 3 weeks for 4 Cycles

DRUG

Nivolumab

IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance

DRUG

Dacarbazine

IV administration every 3 Weeks

Trial Locations (68)

1200

ACTIVE_NOT_RECRUITING

Cliniques Universitaires Saint Luc, Brussels

1307

ACTIVE_NOT_RECRUITING

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

2145

RECRUITING

Westmead Hospital, Sydney

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

ACTIVE_NOT_RECRUITING

Algemene Medische Oncologie UZ, Leuven

3168

RECRUITING

Alfred Health, Melbourne

4102

RECRUITING

Princess Alexander Hospital, Brisbane

6009

RECRUITING

Sir Charles Gairdner Hospital, Perth

8058

RECRUITING

Dermatologische Klinik, USZ Flughafen Geschoss 7 - Klinische Forschung, Zurich

8908

ACTIVE_NOT_RECRUITING

Catalan Institute of Oncology, L'Hospitalet de Llobregat

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

11030

RECRUITING

Northwell Health, Manhasset

12203

ACTIVE_NOT_RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

15706

ACTIVE_NOT_RECRUITING

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

19107

RECRUITING

Thomas Jefferson University, Philadelphia

20133

ACTIVE_NOT_RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

27710

RECRUITING

Duke University Health System, Durham

28046

ACTIVE_NOT_RECRUITING

Hospital Universitario La Paz, Madrid

30342

RECRUITING

Northside Hospital Atlanta, Atlanta

33136

RECRUITING

University of Miami Sylvester Comprehensive Cancer Center, Miami

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

SCRI Oncology Partners, Nashville

41009

ACTIVE_NOT_RECRUITING

Hospital Universitario Virgen Macarena, Seville

44195

RECRUITING

The Cleveland Clinic Foundation, Cleveland

45147

ACTIVE_NOT_RECRUITING

Universitätsklinikum Essen (AöR), Essen

45267

RECRUITING

University of Cincinnati, Cincinnati

46014

ACTIVE_NOT_RECRUITING

Hospital General Universitario Valencia, Valencia

49546

RECRUITING

The Cancer and Hematology Centers, Grand Rapids

50937

ACTIVE_NOT_RECRUITING

Universitätsklinikum Köln, Cologne

52242

RECRUITING

University of Iowa, Iowa City

52621

RECRUITING

Sheba Medical Center, Ramat Gan

53100

ACTIVE_NOT_RECRUITING

AOUS Policlinico Le Scotte, Siena

55337

RECRUITING

Minnesota Oncology Hematology, P.A., Burnsville

55905

RECRUITING

Mayo Clinic, Rochester

63110

RECRUITING

Washington University School of Medicine, St Louis

69120

ACTIVE_NOT_RECRUITING

NCT Heidelberg, Heidelberg

75005

ACTIVE_NOT_RECRUITING

Institut Curie, Paris

75246

RECRUITING

Texas Oncology- DFW, Dallas

75390

RECRUITING

UT Southwestern Medical Center, Dallas

77030

RECRUITING

Houston Methodist Cancer Center, Houston

RECRUITING

MD Anderson Cancer Center, Houston

80045

RECRUITING

University of Colorado Cancer Center, Aurora

80131

ACTIVE_NOT_RECRUITING

Istituto Nazionale dei Tumori Fondazione Pascale, Napoli

80218

RECRUITING

SCRI at HealthONE, Denver

85258

RECRUITING

Honor Health, Scottsdale

90024

RECRUITING

UCLA Medical Center, Los Angeles

90025

RECRUITING

The Angeles Clinic and Research Institute, Los Angeles

91120

RECRUITING

Hadassah Medical Center, Jerusalem

92093

RECRUITING

Moores Cancer Center, La Jolla

94115

RECRUITING

California Pacific Medical Center (CPMC), San Francisco

94143

RECRUITING

University of California San Francisco, San Francisco

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Unknown

RECRUITING

Queen Elizabeth Hospital, Adelaide

ACTIVE_NOT_RECRUITING

The Leon Berard Center, Lyon

T6G 1Z2

RECRUITING

Cross Cancer Institute, University of Alberta, Edmonton

V5Z4C2

RECRUITING

BC Cancer Agency, Vancouver

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

H2X 0C1

RECRUITING

Centre Hospitalier de l'Universite de Montreal- CHUM, Montreal

00168

ACTIVE_NOT_RECRUITING

Fondazione Policlinico Gemelli IRCCS, Roma

2333 ZA

ACTIVE_NOT_RECRUITING

LUMC (Leids Universitair Medisch Centrum), Leiden

80-214

ACTIVE_NOT_RECRUITING

Ośrodek Badań Klinicznych Wczesnych Faz, Uniwersyteckie Centrum Kliniczne w Gdańsku, Gdansk

02-781

ACTIVE_NOT_RECRUITING

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw

G12 0YN

RECRUITING

The Beatson West of Scotland Cancer Centre, Glasgow

CH63 4JY

RECRUITING

The Clatterbridge Cancer Centre NHS Foundation Trust, Metropolitan Borough of Wirral

HA6 2RN

RECRUITING

Mount Vernon Cancer Centre East & North Herts NHS Trust, Northwood

Sponsors

Lead Sponsor

All Listed Sponsors
lead

IDEAYA Biosciences

INDUSTRY

NCT05987332 - IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Biotech Hunter | Biotech Hunter